Trade Genprex, Inc. - GNPX CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0822 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02629% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004068% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 0.01 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 1.9139 |
Open | 1.9139 |
1-Year Change | 154.1% |
Day's Range | 1.7839 - 1.9439 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jul 25, 2024 | 1.9039 | 0.0200 | 1.06% | 1.8839 | 1.9439 | 1.8539 |
Jul 24, 2024 | 1.8639 | -0.0500 | -2.61% | 1.9139 | 1.9339 | 1.8639 |
Jul 23, 2024 | 1.9939 | 0.1100 | 5.84% | 1.8839 | 2.0539 | 1.8839 |
Jul 22, 2024 | 1.9139 | 0.1000 | 5.51% | 1.8139 | 1.9139 | 1.8139 |
Jul 19, 2024 | 1.8939 | -0.0600 | -3.07% | 1.9539 | 1.9739 | 1.8639 |
Jul 18, 2024 | 1.9439 | -0.0700 | -3.48% | 2.0139 | 2.0139 | 1.9239 |
Jul 17, 2024 | 1.9639 | -0.0500 | -2.48% | 2.0139 | 2.0339 | 1.9539 |
Jul 16, 2024 | 2.0139 | 0.0700 | 3.60% | 1.9439 | 2.0239 | 1.9439 |
Jul 15, 2024 | 1.9439 | 0.0700 | 3.74% | 1.8739 | 2.0339 | 1.8339 |
Jul 12, 2024 | 1.8839 | 0.0600 | 3.29% | 1.8239 | 1.8839 | 1.8139 |
Jul 11, 2024 | 1.8039 | 0.0000 | 0.00% | 1.8039 | 1.8339 | 1.7339 |
Jul 10, 2024 | 1.8239 | 0.0300 | 1.67% | 1.7939 | 1.8439 | 1.7939 |
Jul 9, 2024 | 1.7939 | -0.0100 | -0.55% | 1.8039 | 1.8439 | 1.7839 |
Jul 8, 2024 | 1.8239 | -0.0400 | -2.15% | 1.8639 | 1.8839 | 1.8039 |
Jul 5, 2024 | 1.8239 | -0.0900 | -4.70% | 1.9139 | 1.9539 | 1.7839 |
Jul 3, 2024 | 1.8539 | -0.0900 | -4.63% | 1.9439 | 1.9439 | 1.8539 |
Jul 2, 2024 | 1.9439 | 0.0800 | 4.29% | 1.8639 | 1.9739 | 1.8639 |
Jul 1, 2024 | 1.8739 | -0.0200 | -1.06% | 1.8939 | 1.9239 | 1.8739 |
Jun 28, 2024 | 1.8439 | -0.1500 | -7.52% | 1.9939 | 2.0039 | 1.8239 |
Jun 27, 2024 | 1.9439 | -0.0500 | -2.51% | 1.9939 | 2.0939 | 1.9039 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Genprex, Inc. Company profile
About Genprex Inc
Genprex, Inc. is a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogene therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Genprex Inc revenues was not reported. Net loss increased 9% to $13.9M. Higher net loss reflects General and administrative increase of 13% to $8.8M (expense), Research and development increase of 3% to $5.1M (expense), Interest Income decrease of 76% to $4K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.30.
Industry: | Bio Therapeutic Drugs |
1601 Trinity Street, Bldg. B
Suite 3.322
AUSTIN
TEXAS 78712
US
News
![](https://img.capital.com/imgs/articles/192x130x1/Risk-Management-in-Trading.png)
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ECB_0.png)
ECB preview: lack of new data sees markets expecting a hold
Markets expect the ECB to keep rates unchanged in July but expectations for a September cut rise
13:13, 18 July 2024![](https://img.capital.com/imgs/articles/192x130x1/risk_2_1_optimized_450_1.png)
What is an IPO and how does it work?
Learn about what an IPO is, why they are important, and how they work.
07:19, 10 July 2024![](https://img.capital.com/imgs/articles/192x130x1/Stock-1-_1.png)
What are the biggest stock exchanges worldwide?
Discover the largest stock exchanges in the world by market capitalisation, including the Nasdaq Stock Market, the New York Stock Exchange and the London Stock Exchange.
12:44, 9 July 2024![](https://img.capital.com/imgs/articles/192x130x1/ETF-1-_0.png)
Top ETFs
ETFs, or exchange-traded funds, offer traders a versatile gateway into the financial markets.
16:23, 8 July 2024![Lloyds share price forecast: An attractive dividend stock? Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/192x130x1/shutterstock_536730610_0.jpg)
Lloyds forecast: will Lloyds share price return to £1? Third party data forecast
What’s next for Lloyds amid higher inflation and the start of a potential recessionary cycle in the UK?
14:00, 8 July 2024![](https://img.capital.com/imgs/articles/192x130x1/RBNZ.png)
RBNZ Preview: OCR expected to remain unchanged as central bank focuses on inflation
The Reserve Bank of New Zealand meets on Wednesday, July 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
13:25, 8 July 2024People also watch
Still looking for a broker you can trust?
Join the 630,000+ traders worldwide that chose to trade with Capital.com